NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Completed · Phase 3

Conditions studied: Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

In brief

The main objective of this study was to evaluate the efficacy of eplontersen as compared with the historical control of the placebo cohort in the NEURO-TTR trial (NCT01737398/2012-001831-30), in subjects with hereditary transthyretin-mediated amyloidosis polyneuropathy (hATTR-PN). For more information, please visit http://www.neuro-ttransform.com/.

Key facts

Study ID
NCT04136184
Run by
Ionis Pharmaceuticals, Inc.
People needed
168
Starts
2019-12-11
Expected to finish
2023-07-12
Last updated by the study team
2024-12-13

Who can join

Age: 18 and older, up to 82. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.